5 biggest breast cancer takeaways from ASCO 2026
By Kelly MacLeod / Photo illustration by Getty Images
For women following breast cancer research, the American Society of Clinical Oncology’s annual meeting is one of the most important events of the year. The 2026 meeting, held May 29 through June 2 in Chicago, featured more than 7,000 abstracts and drew more than 20,000 attendees from around the world. The research covered everything from new drugs to artificial intelligence, immunotherapy and strategies for reducing treatment-related side effects.
For breast cancer in particular, the meeting offered a striking combination of progress and personalization. Researchers presented evidence that some women with high-risk disease may be able to avoid chemotherapy, while new targeted treatments are expanding options for people with difficult-to-treat cancers. Other studies focused on detecting treatment resistance earlier and using artificial intelligence to make treatment decisions more precise.
The biggest message from ASCO 2026 may be this: Breast cancer treatment is becoming less one-size-fits-all.
Here are five of the most important takeaways.
1. More women may be able to safely avoid chemotherapy
One of the most consequential breast cancer findings came from the phase 3 OPTIMA trial.
The study looked at people with clinically high-risk, estrogen receptor-positive (ER-positive), HER2-negative early breast cancer — a group that has traditionally been considered likely to benefit from chemotherapy. Researchers wanted to know whether genomic testing could identify women whose tumors were actually less likely to benefit from chemotherapy.
Researchers used a test that looks at the genes in a tumor to help determine which women were most likely to benefit from chemotherapy. Women whose results suggested a lower risk were able to skip chemotherapy and take hormone therapy instead, while those considered at higher risk received chemotherapy followed by hormone therapy.
The results were encouraging: About 68% of women who initially appeared to be at high risk were found to have a lower-risk cancer and were able to avoid chemotherapy. Five years later, their outcomes were nearly as good as those of women who received chemotherapy. BCRF called the findings potentially practice-changing.
The study builds on years of research showing that genetic testing can help doctors make more personalized treatment decisions. What made OPTIMA especially notable was that it included women whose cancers appeared more serious based on traditional measures, including some with cancer in several lymph nodes or larger tumors.
According to summaries from BCRF on the conference, this could mean that a diagnosis that looks high risk based on traditional measures may not necessarily mean chemotherapy is the best choice.
That does not mean chemotherapy is becoming obsolete. It means doctors may have a better way to identify who is most likely to benefit from it.
The distinction matters because chemotherapy can produce both short- and long-term side effects. If a woman’s tumor biology indicates that chemotherapy is unlikely to add meaningful benefit, avoiding it could spare her treatment without substantially compromising cancer control.
OPTIMA also offered important information about premenopausal women age 40 and older receiving ovarian function suppression, a group in which genomic testing has historically been less established.
BCRF says the larger trend is: Instead of automatically treating based on how threatening a cancer looks under a microscope or on a scan, doctors are increasingly asking what the cancer’s molecular characteristics reveal about its likely response to treatment.
2. Triple-negative breast cancer is getting more treatment options
Triple-negative breast cancer has long been one of the more difficult forms of breast cancer to treat because it lacks some of the targets that treatments focus on. But research presented at ASCO 2026 offered encouraging signs that the treatment landscape is changing.
Several studies showed that newer targeted drugs, particularly a class of treatments known as antibody-drug conjugates, can help slow the disease and, in some cases, extend survival for women with advanced triple-negative breast cancer. Researchers also found that combining these newer drugs with immunotherapy may offer additional benefits for some patients.
The progress isn’t limited to advanced disease. Longer-term results from a major clinical trial continued to show that adding immunotherapy to chemotherapy can improve outcomes for people with high-risk, early-stage triple-negative breast cancer.
The bigger takeaway: Women with triple-negative breast cancer have more treatment options than they did just a few years ago, and researchers are finding new ways to combine therapies to make them work better.
3. Hormone-positive breast cancer is more precisely targeted
Most breast cancers are hormone receptor-positive. For these cancers, endocrine therapy has long been a cornerstone of treatment. But researchers are increasingly looking for ways to make hormone therapy more effective — and to stay one step ahead of resistance.
One of the most interesting findings presented at ASCO came from the SERENA-6 trial, involving hormone receptor-positive, HER2-negative breast cancer.
Researchers used circulating tumor DNA, or ctDNA, to detect an emerging ESR1 mutation. ESR1 mutations can be a sign that a breast cancer is becoming resistant to certain endocrine therapies.
Instead of waiting for the cancer to progress on scans, researchers switched patients to a newer oral estrogen receptor degrader, while continuing a CDK4/6 inhibitor.
The approach helped keep the cancer from progressing for longer than standard treatment, giving patients an additional time before their disease worsened. After two years, about one-third of patients taking the newer treatment had no signs of their cancer progressing. The results suggest that monitoring the cancer at a molecular level may allow doctors to spot treatment resistance earlier and switch therapies before the disease becomes more difficult to control.
The importance goes beyond one drug. It demonstrates the possibility of monitoring a cancer’s molecular evolution and changing treatment before a scan shows that the cancer has clearly progressed.
That could represent an important change in the way metastatic breast cancer is managed.
Another hormone-positive development came from the phase 3 lidERA trial. Researchers evaluated another next-generation oral estrogen receptor degrader in people with ER-positive, HER2-negative early breast cancer after surgery.
The study found a 30% reduction in the risk of invasive recurrence or death compared with standard endocrine therapy. BCRF reported that the benefit was seen regardless of menopausal status and that the risk of metastatic disease was reduced by 42% in premenopausal women and 24% in postmenopausal women.
The treatment also appeared easier for some patients to remain on. Musculoskeletal pain is one of the reasons people discontinue endocrine therapy, and BCRF reported that stopping treatment because of such pain was less than half as common than with standard endocrine therapy in the study.
That could be meaningful for women facing years of endocrine treatment.
4. Immunotherapy research is moving beyond adding a drug
Immunotherapy has already changed the treatment landscape for some breast cancers, particularly TNBC. But researchers at ASCO 2026 were asking a more sophisticated question: How can we make the immune system work better against breast cancer?
One intriguing approach came from the P-RAD trial. Researchers tested whether giving radiation before immunotherapy could help “prime” the immune system. The trial examined two radiation doses before pembrolizumab and measured T-cell infiltration, an indication that the immune system had been activated within the tumor.
Both radiation doses increased T-cell infiltration: 80% at the 9 Gy dose and 82% at the 24 Gy dose. BCRF described the results as encouraging evidence that radiation may help prime the immune system to respond more effectively to immunotherapy.
The research is ongoing and this is still experimental, and women should not interpret it as evidence that radiation plus immunotherapy is appropriate for every breast cancer. But it represents an important direction for the field. Researchers are increasingly trying to understand not simply which drugs work, but how different treatments can be sequenced or combined to make each other more effective.
5. AI is moving closer to the clinic
Artificial intelligence may sound far removed from the day-to-day experience of breast cancer treatment, but ASCO 2026 offered examples of how it could eventually influence decisions made by doctors.
BCRF highlighted two presentations involving AI and breast cancer.
In one, a BCRF investigator demonstrated that AI could extract predictive information directly from pathology slides and clinical data. The goal is potentially to identify which patients are likely to need chemotherapy without requiring additional testing.
In another presentation, a researcher at Memorial Sloan Kettering demonstrated an AI approach that could identify patients at particularly high risk of developing brain metastases before those metastases become clinically apparent. That could potentially allow doctors to intervene earlier.
These are not yet reasons for patients to expect an AI-generated treatment plan at their next appointment. Rather, they illustrate where the technology is heading. The hope is significant: AI could potentially analyze information that is too complex or extensive for a human to process easily and identify patterns that help doctors make more informed decisions.
But as with genomic testing and experimental drugs, validation matters. A promising research finding is not automatically a proven clinical tool.
What it all means
If there was one overarching theme at ASCO 2026, it was personalization.
For some women, that could mean less treatment. The OPTIMA findings suggest that genomic information may identify patients who can safely avoid chemotherapy even when traditional clinical factors make their cancer appear high risk.
For others, it could mean more sophisticated treatment. Women with metastatic TNBC now have an expanding collection of antibody-drug conjugates and immunotherapy strategies to consider.
For women with hormone-positive disease, researchers are developing ways to detect treatment resistance earlier and switch therapies before obvious progression occurs. And across breast cancer, researchers are beginning to use AI to extract additional information from pathology and clinical records.
Even the encouraging findings come with an important qualification: A promising clinical-trial result does not necessarily change standard treatment overnight.
Some treatments discussed at ASCO remain experimental, and some findings require longer follow-up before researchers know whether they will ultimately improve overall survival.
Still, the direction is unmistakable.
Breast cancer treatment is moving away from the idea that every woman with the same stage of cancer should receive essentially the same treatment. Instead, researchers are working toward a system in which treatment is determined by the tumor’s molecular characteristics, the patient’s individual risk and the likelihood that a particular therapy will actually help.
For women diagnosed with breast cancer, that means conversations with their care teams are becoming more important — and potentially more detailed.
Questions about genomic testing, hormone-receptor and HER2 status, mutations such as ESR1, eligibility for targeted therapies and participation in clinical trials may all be relevant depending on the diagnosis.
The ultimate goal is not simply to develop more treatments.
It is to determine which treatment each woman needs, when she needs it and when she can safely do without it.
This article is for informational and educational purposes only and is not intended to provide medical advice, diagnosis or treatment recommendations. Breast cancer is highly individual, so readers should talk with their doctor or qualified health care professional about their diagnosis, treatment options and any questions raised by this article.
